World's Largest Resource for Cardiovascular Perfusion

+1 888-499-5672 Login

Variability in Anticoagulation Management of Patients on Extracorporeal Membrane Oxygenation: An International Survey

Blood Management, Main Zone, Mobile Zone, Perfusion Zone

1 min read

OBJECTIVE: The objective of this study was to determine current practices of anticoagulation in patients on extracorporeal membrane oxygenation.

DESIGN: Internet-based cross-sectional survey distributed between November 2010 and May 2011.

SETTING: Extracorporeal Life Support Organization-registered extracorporeal membrane oxygenation centers internationally.

PARTICIPANTS: Extracorporeal membrane oxygenation medical directors and coordinators.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: There were 121 responses from extracorporeal membrane oxy genation medical directors and coordinators at 187 Extracorporeal Life Support Organization centers with access to the survey. Eighty-four of 117 (72%) respondents reported having a written institutional extracorporeal membrane oxy genation protocol for both anticoagulation and blood product management at their institutions. Sixty-nine of 117 (59%) respondents reported use of tip-to-tip or partially heparin-bonded circuits. Unfractionated heparin was used at all centers; only 8% of respondents indicated use of alternative anticoagulation medications in the six months prior to the survey. The preferred method of anticoagulation monitoring was the serial measurement of activated clotting time, as reported by 97% of respondents. In this survey, 82% of respondents reported antithrombin III testing, 65% reported anti-factor Xa testing, and 43% reported use of thromboelastography during extracorporeal membrane oxy genation. Goal ranges for these three tests and interventions triggered by out-of-range values were found to be variable.

CONCLUSIONS: Extracorporeal membrane oxy genation anticoagulation management policies vary widely by center. The majority of extracorporeal membrane oxy genation programs employ activated clotting time as the preferred anticoagulation monitoring tool. The coagulation system is also monitored using more specific markers such as antithrombin III, anti-factor Xa, and thromboelastography by a large number of centers. Future research is needed to elucidate optimal anticoagulation management and improve outcomes.

Perfusion.com

You may also like

Blood Management, Perfusion Devices, Perfusion Zone, Tiny Perfusion Letter

Can We Rely on the Activated Clotting Time to Measure Heparin Anticoagulation? A Clinical Evaluation of Two ACT Monitors

ACT monitors demonstrate unacceptable bias differences, combined with wide limits of agreement. The ACT response correlated with hematocrit, but not with the actual heparin concentration.

1 min read

Circuit Surfers, Clinical Issues

From Japan [ 6 ] Images in Cardiovascular Medicine

1 min read

Education Zone, Pediatric Zone, Perfusion Zone, Tiny Perfusion Letter

Study Protocol: Nitric Oxide During Cardiopulmonary Bypass to Improve Recovery in Infants With Congenital Heart Defects (NITRIC Trial): A Randomised Controlled Trial

Congenital heart disease (CHD) is a major cause of infant mortality. Many infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass (CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syndrome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and improved recovery.

1 min read